Botulinum toxin for chronic migraine: Clinical trials and technical aspects

Cristina Tassorelli, Grazia Sances, Micol Avenali, Roberto De Icco, Daniele Martinelli, Vito Bitetto, Giuseppe Nappi, Giorgio Sandrini

Research output: Contribution to journalArticle

Abstract

OnabotulinumtoxinA has been approved for the prophylaxis of chronic migraine following the demonstration of efficacy in two large controlled trials. Data collected from pragmatic studies in the real-life setting have contributed important additional information useful for the management of this group of extremely disabled and challenging patients. The main findings from these studies are presented and discussed.

Original languageEnglish
JournalToxicon
DOIs
Publication statusE-pub ahead of print - Sep 4 2017

    Fingerprint

Keywords

  • Journal Article

Cite this